Gleevec, which was just approved for treating leukemia, also shows promise against a type of stomach cancer . The Food and Drug Administration approved the use of a promising anti-leukemia drug for treatment of a relatively rare form of abdominal cancer. The drug, Gleevec, administered as a pill once a day, is effective in treating both forms of cancer because of its ability to target and kill cancer cells without attacking healthy cells and causing severe side effects. //

Approved last spring for a common type of adult leukemia, Gleevec can now be used to treat gastrointestinal stromal tumors, or GIST, which affect as many as 5,000 people in the US each year. Studies have shown it to be as effective in treating chronic cases of GIST as it has been in treating chronic myelogenous leukemia (CML).

Researchers reported 59 percent of patients with advanced-stage GIST went into remission and up to 75 percent showed some type of improvement with limited side effects. GIST accounts for about two percent of all abdominal cancers. If caught early, these tumors can usually be removed surgically, but growths often return. According to its manufacturer, Novartis Oncology, Gleevec also is being studied as a possible treatment for prostate cancer, small-cell lung cancer and a rare type of brain cancer.
'"/>




Page: 1
Related medicine news :

1. Cyclosporin A Treats Leukemia Complications
2. Aspirin Lowers Leukemia Risk
3. Hope for Chemo-Resistant Leukemia Patients
4. Genes Found To Help Leukemia Treatment
5. Looking Towards More Effective Leukemia Treatment
6. Diet Found To Offer Protection Against Leukemia
7. Exposure To Night Light may Increase The Risk Of Leukemia
8. Skin Allergies Found To Increase The Risk Of Leukemia
9. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
10. Night Light Found To Increase The Risk Of Leukemia
11. Treating Leukemia With Natural Cells